Stepwise estrogen suppression manipulating the estrostat

Journal of Steroid Biochemistry and Molecular Biology

Volumn 79, Issue 1-5, 2001, Pages 127-132

  Lonning, Per Eystein ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Aromatase; Breast cancer; Estradiol; Estrogen; Inhibition; Resistance

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; DIETHYLSTILBESTROL; ESTRADIOL; EXEMESTANE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

ADRENALECTOMY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CELL STRAIN MCF 7; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CROSS RESISTANCE; DRUG EFFICACY; ESTROGEN BLOOD LEVEL; GENE EXPRESSION; HORMONAL REGULATION; HUMAN; HYPOPHYSECTOMY; POSTMENOPAUSE; PREMENOPAUSE; SENSITIZATION; SIGNAL TRANSDUCTION;

ADAPTATION, PHYSIOLOGICAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DIETHYLSTILBESTROL; ENZYME INHIBITORS; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; OVARIECTOMY; RESEARCH DESIGN;

MINK CELL FOCUS-FORMING VIRUS;

EID: 17344379365     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(01)00152-2     Document Type: Conference Paper

References (65)

1. Treatment of breast cancer with aromatase inhibitors - Current status and future prospects
2. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis
3. Progestins in breast cancer treatment
4. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients
5. Castration for primary inoperable or recurrent breast carcinoma
6. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study
7. Ovarian ablation in early breast cancer: Overview of the randomised trials
8. The third-generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer
9. Aromatization inhibition alone or in combination with GmRH agonists for the treatment of premenopausal breast cancer patients
10. Second and third line hormontherapy in advanced post-menopausal breast cancer: A multicenter randomized trial comparing medrozyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen
11. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer
12. A phase II confirmatory study of antitumor efficacy and safety of exemestane (EXE) as third-line hormonal treatment of postmenopausal patients (pts) with metastatic breast cancer (MBC) refractory to tamoxifen and megace
13. Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy
14. ®), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
15. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post menopausal patients with breast cancer
16. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
17. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer
18. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
19. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
20. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
21. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
22. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment
23. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: Clinical and endocrine effects
24. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings
25. Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide
26. Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide
27. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial
28. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy
29. Beneficial response to pituitary ablation following aminoglutethimide
30. Aromatase inhibition with 4-OH and rostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer
31. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients
32. Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients
33. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase study
34. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer
35. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells
36. Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: Role of very high affinity tissue uptake
37. Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue
38. Concentration of endogenous oestradiol as related to oestradiol receptor sites in breast tumor cytosol
39. Aromatase 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women
40. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer
41. Long term estrogen deprivation (LTED) enhances aromatase activity in breast cancer cells
42. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo
43. Antiaromatase agents: Preclinical data and neoadjuvant therapy
44. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole
45. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy
46. Use of alternative promoters to express the aromatase cytochrome p450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients
47. Identification of a promoter that controls aromatase expression in human breast cancer and adipose stromal cells
48. Use of tissue-specific promoters in the regulation of aromatase cytochrome p450 gene expression in human testicular and ovarian sex cord tumors as well as in normal fetal and adult gonads
49. Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4
50. TGF-beta 1 stimulates expression of the aromatase (CYP19) gene in human osteoblast-like cells and THP-1 cells
51. Control of aromatase activity in breast cancer cells: The role of cytokines and growth factors
52. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE(2) via cyclic AMP, reading to activation of promoter II of the CYP19 (aromatase) gene
53. Influence of synthetic oestrogens upon advanced malignant disease
54. Massive estrogen administration in premenopausal women with metastatic breast cancer
55. Randomized clinical trial of diethylstilstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer
56. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture
57. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine treatment
58. Estrogen induces apoptosis in human breast cancer cells adapted to long term estrogen deprivation
59. Letrozole suppresses plasma estrogen levels in postmenopausal breast cancer patients more completely than anastrozole
60. Letrozole achieves more complete inhibition of whole body aromatisation than anastrozole
61. Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study
62. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo
63. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue
64. Molecular portraits of human breast tumours
65. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications